Gerald hasn't given us any "quantitative revenue g
Post# of 30029
Posted On: 11/10/2014 4:29:07 PM
Gerald hasn't given us any "quantitative revenue guidance" for Lympro. He has been very vague. So no one knows for sure what AMBS's value is or will be in the near future.
I still maintain LymPro is what drives our pps in the near future. If LymPro doesn't launch and start bringing in modest revenues in Q1 2015, nothing else that MANF or Eltoprazine do will matter. But, if Lympro launches and starts signing up pharmas doing AD trials, even if the Q1 revenue is very modest, then everything changes. Then investors will know that Lympro revenue will get crazy by Q1 of 2016 and the color of everything changes to green!
Eltoprazine's new phase 2b trial will seem more exciting if Lympro is signing up pharmas and the MANF orphan will seem more exciting based on Lympro's success as well.
The question is how soon will we get the Lympro data from the tests in December? I think everything starts from there.
I still maintain LymPro is what drives our pps in the near future. If LymPro doesn't launch and start bringing in modest revenues in Q1 2015, nothing else that MANF or Eltoprazine do will matter. But, if Lympro launches and starts signing up pharmas doing AD trials, even if the Q1 revenue is very modest, then everything changes. Then investors will know that Lympro revenue will get crazy by Q1 of 2016 and the color of everything changes to green!
Eltoprazine's new phase 2b trial will seem more exciting if Lympro is signing up pharmas and the MANF orphan will seem more exciting based on Lympro's success as well.
The question is how soon will we get the Lympro data from the tests in December? I think everything starts from there.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼